Blog
RSS FeedPosted by Michael Wonder on 05 Nov 2020
Skin cancer drug not cost effective for routine NHS use
5 November 2020 - A consultation on the draft recommendations has now begun until Tuesday 24 November 2020. ...
Posted by Michael Wonder on 04 Nov 2020
NICE updates guidance for nivolumab for melanoma
4 November 2020 - NICE has updated its guidance for nivolumab for adjuvant treatment of completely resected melanoma with lymph ...
Posted by Michael Wonder on 04 Nov 2020
NICE publishes first technology assessment guidance for oesophageal cancer
4 November 2020 - NICE publishes more guidance on the use of nivolumab. ...
Posted by Michael Wonder on 01 Nov 2020
BMS appeals final appraisal document for nivolumab for non-small cell lung cancer
30 October 2020 - The appeal will be heard on 1 December 2020. ...
Posted by Michael Wonder on 30 Oct 2020
ICR welcomes NICE’s decision to reassess abiraterone acetate as first-line treatment for advanced prostate cancer
29 October 2020 - The Institute of Cancer Research, London, has welcomed the announcement by NICE that it will reconsider ...
Posted by Michael Wonder on 27 Oct 2020
NICE publishes appraisal consultation document for avapritinib
27 October 2020 - Avapritinib is used to treat patients with an unresectable or metastatic gastro-intestinal stromal tumour. ...
Posted by Michael Wonder on 26 Oct 2020
ICR urges change as NICE rejects Keytruda plus chemotherapy
23 October 2020 - The Institute for Cancer Research has called for change in the way immunotherapy drugs are researched ...
Posted by Michael Wonder on 26 Oct 2020
NICE recommends Bayer’s Nubeqa (darolutamide), a new treatment option for non-metastatic castration-resistant prostate cancer
23 October 2020 - Positive recommendation based on Phase 3 ARAMIS trial data in which darolutamide plus androgen deprivation therapy showed ...
Posted by Michael Wonder on 21 Oct 2020
NICE recommended use of Opdivo for another indication
20 October 2020 - This marks the tenth NICE recommendation for nivolumab. ...
Posted by Michael Wonder on 07 Oct 2020
NICE terminates yet another appraisal
7 October 2020 - 9 of the last 20 published technology appraisals have been terminated. ...
Posted by Michael Wonder on 23 Sep 2020
NICE publishes final guidance for another Roche cancer medicine
23 September 2020 - This time it is for polatuzumab vedotin (Polivy) for patients with non-Hodgkin's lymphoma. ...
Posted by Michael Wonder on 22 Sep 2020
NICE publishes draft guidance on new use for Kyprolis
22 September 2020 - The guidance relates to the use of carfilzomib with dexamethasone and lenalidomide for patients with previously ...
Posted by Michael Wonder on 18 Sep 2020
BMS' Opdivo wins new NICE lung cancer backing
18 September 2020 - NICE has published draft guidance recommending Bristol-Myers Squibb's Opdivo (nivolumab) as a second-line treatment option for ...
Posted by Michael Wonder on 11 Sep 2020
Improved agreement means NICE now recommends lung cancer treatment
11 September 2020 - Thousands of people with non-small-cell lung cancer (NSCLC) will benefit from draft guidance published today by NICE. ...
Posted by Michael Wonder on 08 Sep 2020
NICE releases initial guidance for another indication for lenalidomide
8 September 2020 - This time, it is for use as maintenance treatment after autologous stem cell transplantation for patients ...